Danaher Corporation vs Google Inc — how do they compare? Danaher Corporation trades at $206.36 (market cap $145.83B), while Google Inc trades at $340.79 (market cap $4.20T). The key difference: Google Inc is far larger — about 28.8× Danaher Corporation's market cap, and Danaher Corporation pays the higher dividend (0.77%). Which is the better fit depends on your goals.
| DHR | GOOG | |
|---|---|---|
Market Cap | $145.83B | $4.20T |
Sector | Health | Technology |
52-Week High | $242.05 | $399.06 |
52-Week Low | $161.91 | $200.19 |
Enterprise Value | $168.04B | $4.09T |
Dividend Yield | 0.77% | 0.26% |
Volume | — | 1,511,127 |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Alphabet (GOOG) trades at $340.22, down 4.39% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals, with revenue growing from $282.8B in 2022 to $402.84B in 2025 and net income margin expanding to 32.8%. Recent earnings beats and a consensus analyst price target of $431.67 suggest upside potential, though high capital expenditure plans and regulatory scrutiny pose risks.
The outlook remains positive due to robust AI adoption, with Gemini reaching 1 billion users, but investors face headwinds from elevated capex and antitrust investigations. Wall Street sentiment is overwhelmingly bullish, with 86.84% of analysts rating it a buy, highlighting growth prospects amid competitive and regulatory challenges.
Trailing returns across standard periods
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →